SCCM
TEVA icon

Schafer Cullen Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Schafer Cullen Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,895
Closed -$214K – 293
2016
Q4 		$214K Sell
5,895
-4,670
-44% -$186K ﹤0.01% 273
2016
Q3 		$486K Buy
10,565
+3,205
+44% +$167K 0.01% 221
2016
Q2 		$370K Sell
7,360
-36,095
-83% -$1.92M ﹤0.01% 237
2016
Q1 		$2.33M Sell
43,455
-10,632
-20% -$624K 0.03% 147
2015
Q4 		$3.55M Sell
54,087
-18,025
-25% -$1.11M 0.04% 131
2015
Q3 		$4.07M Sell
72,112
-75,443
-51% -$4.89M 0.05% 133
2015
Q2 		$8.72M Buy
147,555
+63
+0% +$3.89K 0.09% 98
2015
Q1 		$9.19M Buy
147,492
+17,677
+14% +$1.03M 0.09% 92
2014
Q4 		$7.47M Sell
129,815
-59,330
-31% -$3.31M 0.09% 89
2014
Q3 		$10.2M Sell
189,145
-530
-0.3% -$28.1K 0.1% 84
2014
Q2 		$9.94M Sell
189,675
-2,967
-2% -$152K 0.09% 88
2014
Q1 		$10.2M Buy
192,642
+92,510
+92% +$4.28M 0.1% 88
2013
Q4 		$4.01M Buy
100,132
+12,511
+14% +$493K 0.04% 172
2013
Q3 		$3.31M Buy
87,621
+2,812
+3% +$110K 0.04% 190
2013
Q2 		$3.33M Buy
+84,809
New +$3.3M 0.04% 176

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Schafer Cullen Capital Management's TEVA Position: Q1 2017 in Review

Schafer Cullen Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 5,895 shares — an estimated $214K sold.

Schafer Cullen Capital Management first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $10.2M in Q1 2014. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Schafer Cullen Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Schafer Cullen Capital Management sold 5,895 Teva Pharmaceuticals shares in Q1 2017, an estimated $214K.
  • Schafer Cullen Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Schafer Cullen Capital Management's Teva Pharmaceuticals position peaked at $10.2M in Q1 2014.
  • 686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Schafer Cullen Capital Management's 13F filing for Q1 2017, filed 11 May 2017.